These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 23126266)
1. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy. Nittayananta W; Kemapunmanus M; Yangngam S; Talungchit S; Sriplung H J Oral Pathol Med; 2013 Mar; 42(3):208-15. PubMed ID: 23126266 [TBL] [Abstract][Full Text] [Related]
2. Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy. Nittayananta W; Kemapunmanus M; Amornthatree K; Talungchit S; Sriplung H J Oral Pathol Med; 2013 Jan; 42(1):53-60. PubMed ID: 22680235 [TBL] [Abstract][Full Text] [Related]
3. Salivary secretory leukocyte protease inhibitor increases in HIV infection. Lin AL; Johnson DA; Stephan KT; Yeh CK J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833 [TBL] [Abstract][Full Text] [Related]
4. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Chattopadhyay A; Gray LR; Patton LL; Caplan DJ; Slade GD; Tien HC; Shugars DC Infect Immun; 2004 Apr; 72(4):1956-63. PubMed ID: 15039315 [TBL] [Abstract][Full Text] [Related]
5. Effects of long-term use of antiretroviral therapy on the prevalence of oral Epstein-Barr virus. Amornthatree K; Sriplung H; Mitarnun W; Nittayananta W J Oral Pathol Med; 2012 Mar; 41(3):249-54. PubMed ID: 21981060 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Skott P; Lucht E; Ehnlund M; Björling E Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760 [TBL] [Abstract][Full Text] [Related]
7. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Baqui AA; Meiller TF; Falkler WA Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568 [TBL] [Abstract][Full Text] [Related]
9. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984 [TBL] [Abstract][Full Text] [Related]
10. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age. Shugars DC; Watkins CA; Cowen HJ Gerontology; 2001; 47(5):246-53. PubMed ID: 11490143 [TBL] [Abstract][Full Text] [Related]
11. Expression of oral cytokines in HIV-infected subjects with long-term use of antiretroviral therapy. Nittayananta W; Amornthatree K; Kemapunmanus M; Talungchit S; Sriplung H Oral Dis; 2014 Apr; 20(3):e57-64. PubMed ID: 23718561 [TBL] [Abstract][Full Text] [Related]
12. The role of the oral environment in HIV-1 transmission. Shugars DC; Wahl SM J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760 [TBL] [Abstract][Full Text] [Related]
13. Effects of long-term use of HAART on oral health status of HIV-infected subjects. Nittayananta W; Talungchit S; Jaruratanasirikul S; Silpapojakul K; Chayakul P; Nilmanat A; Pruphetkaew N J Oral Pathol Med; 2010 May; 39(5):397-406. PubMed ID: 20202089 [TBL] [Abstract][Full Text] [Related]
14. Changes in oral cytokeratin expression in HIV-infected subjects with long-term use of HAART. Nittayananta W; Mitarnun W; Talungchit S; Sriplung H Oral Dis; 2012 Nov; 18(8):793-801. PubMed ID: 22747944 [TBL] [Abstract][Full Text] [Related]
15. Changes of alpha1-protease inhibitor and secretory leukocyte protease inhibitor levels in gingival crevicular fluid before and after non-surgical periodontal treatment. Nakamura-Minami M; Furuichi Y; Ishikawa K; Mitsuzono-Tofuku Y; Izumi Y Oral Dis; 2003 Sep; 9(5):249-54. PubMed ID: 14628892 [TBL] [Abstract][Full Text] [Related]
16. Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations. Rahman S; Pierce Campbell CM; Torres BN; O'Keefe MT; Ingles DJ; Villa LL; Carvalho da Silva RJ; Cintra RC; Lazcano-Ponce E; Salmeron J; Quiterio M; Giuliano AR Oral Dis; 2016 Nov; 22(8):781-790. PubMed ID: 27470907 [TBL] [Abstract][Full Text] [Related]
17. Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort. Pierce Campbell CM; Giuliano AR; Torres BN; O'Keefe MT; Ingles DJ; Anderson RL; Teras LR; Gapstur SM Oral Oncol; 2016 Apr; 55():1-5. PubMed ID: 27016010 [TBL] [Abstract][Full Text] [Related]
18. Quantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwash. Pierce Campbell CM; Guan W; Sprung R; Koomen JM; O'Keefe MT; Ingles DJ; Abrahamsen M; Giuliano AR J Immunol Methods; 2013 Dec; 400-401():117-21. PubMed ID: 24140751 [TBL] [Abstract][Full Text] [Related]
19. Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis. Cox SW; Rodriguez-Gonzalez EM; Booth V; Eley BM J Periodontal Res; 2006 Oct; 41(5):477-85. PubMed ID: 16953825 [TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. Jana NK; Gray LR; Shugars DC J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]